ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
Acta Pharmaceutica Sinica B · 2025-06 · 15 (6) · 3092-3106
DOI: 10.1016/j.apsb.2025.04.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-06. Verfasst von Yuhua Deng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, the First People's Hospital of Foshan, Foshan 528100, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Chemotherapy is currently the mainstay of systemic management for triple-negative breast cancer (TNBC), but chemoresistance significantly impacts patient outcomes. Our research indicates that Doxorubicin (Dox)-resistant TNBC cells exhibit increased glycolysis and ATP generation compared to their parental cells, with this metabolic shift contributing to chemoresistance. We discovered that ALKBH3, an m1A demethylase enzyme, is crucial in regulating the enhanced glycolysis in Dox-resistant TNBC cells. Knocking down ALKBH3 reduced ATP generation, glucose consumption, and lactate production, implicating its involvement in mediating glycolysis. Further investigation revealed that aldolase A (ALDOA), a key enzyme in glycolysis, is a downstream target of ALKBH3. ALKBH3 regulates ALDOA mRNA stability through m1A demethylation at the 3'-untranslated region (3'UTR). This methylation negatively affects ALDOA mRNA stability by recruiting the YTHDF2/PAN2-PAN3 complex, leading to mRNA degradation. The ALKBH3/ALDOA axis promotes Dox resistance both in vitro and in vivo. Clinical analysis demonstrated that ALKBH3 and ALDOA are upregulated in breast cancer tissues, and higher expression of these proteins is associated with reduced overall survival in TNBC patients. Our study highlights the role of the ALKBH3/ALDOA axis in contributing to Dox resistance in TNBC cells through regulation of ALDOA mRNA stability and glycolysis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, the First People's Hospital of Foshan, Foshan 528100, China.
- Institute of Translational Medicine Research, the First People's Hospital of Foshan, Foshan 528100, China.
- Guangdong Medical University, Zhanjiang 524000, China.
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 5100…
Förderung
- Natural Science Foundation of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Deng, Y., Chen, Z., Chen, P., Xiong, Y., Zhang, C., Wu, Q., Huang, H., Yang, S., Zhang, K., He, T., Li, W., Ye, G., Luo, W., Wang, H., & Zhou, D. (2025). ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells. Acta Pharmaceutica Sinica B, 15(6), 3092-3106. https://doi.org/10.1016/j.apsb.2025.04.018
Vancouver
Deng Y, Chen Z, Chen P, Xiong Y, Zhang C, Wu Q, et al. ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells. Acta Pharmaceutica Sinica B. 2025;15(6):3092-3106. doi:10.1016/j.apsb.2025.04.018
BibTeX
@article{Deng2025,
author = {Deng, Yuhua and Chen, Zhiyan and Chen, Peixian and Xiong, Yaming and Zhang, Chuling and Wu, Qiuyuan and Huang, Huiqi and Yang, Shuqing and Zhang, Kun and He, Tiancheng and Li, Wei and Ye, Guolin and Luo, Wei and Wang, Hongsheng and Zhou, Dan},
title = {ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells},
journal = {Acta Pharmaceutica Sinica B},
year = {2025},
volume = {15},
number = {6},
pages = {3092--3106},
doi = {10.1016/j.apsb.2025.04.018}
}
EUVIMED